Journal profile · PERIPHERAL VASCULAR DISEASE
High Blood Pressure & Cardiovascular Prevention
ISSN 1120-9879 · eISSN 1179-1985 · Springer Nature · 6 issues per year
High Blood Pressure & Cardiovascular Prevention: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.9 (journal website); hybrid open access; APC about USD 2,890; median 74 days to acceptance (88 articles, last 24 months); 76 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
High Blood Pressure & Cardiovascular Prevention is published by Springer Nature and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Blood Pressure and Hypertension Studies, Hormonal Regulation and Hypertension and Cardiovascular Health and Disease Prevention, together about 42.2% of its articles. Its main subfields are Cardiology and Cardiovascular Medicine. (generated from OpenAlex topic counts and CAS ranking data)
High Blood Pressure & Cardiovascular Prevention promotes knowledge, update and discussion in the field of hypertension and cardiovascular disease prevention, by providing a regular programme of independent review articles covering key aspects of the management of hypertension and cardiovascular diseases. The journal includes: Invited 'State of the Art' reviews. Expert commentaries on guidelines, major trials, technical advances.Presentation of new intervention trials design.'Pros and Cons' or round tables on controversial issues.Statements on guidelines from hypertension and cardiovascular scientific societies.Socio-economic issues.Cost/benefit in prevention of cardiovascular diseases.Monitoring of healthcare systems.News and views from the Italian Society of Hypertension (including abstracts).All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.
From the journal's Aims & Scope
Research area (LetPub): PERIPHERAL VASCULAR DISEASE
Editor-in-chief Massimo VolpePublisher website
Editorial board by country: none in mainland China; most named Italy 55, United States 10, Switzerland 6, Germany 4, Spain 4 (104 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Blood Pressure and Hypertension StudiesMedicine25.9%
- Hormonal Regulation and HypertensionMedicine8.8%
- Cardiovascular Health and Disease PreventionMedicine7.5%
- Heart Rate Variability and Autonomic ControlMedicine5.6%
- Sodium Intake and HealthNursing5.5%
- Cardiovascular Function and Risk FactorsMedicine5%
- Cardiovascular Disease and AdiposityMedicine4.2%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Peripheral Vascular Disease | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Peripheral Vascular Disease | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 2.9Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.8Publisher website ·
- CiteScore 2026-06
- 5.5LetPub ·
- SJR 2026-06
- 0.82LetPub ·
- SNIP 2026-06
- 0.94LetPub ·
- h-index
- 47OpenAlex ·
- i10-index
- 311OpenAlex ·
- 2-year mean citedness
- 2.6OpenAlex ·
- Self-citation rate
- 10.3%LetPub ·
- Share of gold OA articles
- 34.55%LetPub ·
Volume
- Articles per year
- 66LetPub ·
- Articles per year (publisher)
- 2,025Publisher website ·
- Downloads per year (publisher) 2025
- 297,500Publisher website ·
Articles by year OpenAlex count · 1,612 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 46 | 24 | 13 |
| 2025 | 76 | 33 | 178 |
| 2024 | 80 | 27 | 335 |
| 2023 | 60 | 30 | 670 |
| 2022 | 60 | 30 | 746 |
| 2021 | 70 | 36 | 977 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
74 daysMedian, submission to acceptance · P25–P75 45 days – 107 days
- Acceptance to online
- median 27 days (88 articles)
- Submission to online
- median 105 days
- Sample
- 88 articles with submission and acceptance dates (151 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 5 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 2,890 / EUR 4,290 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
Article types accepted15, with length limits
- case reportReview ArticlesOverview papers on selected topics. Review articles are in general invited by the editors but suggestions by interested individuals may also be c…main text ≤ 2,000 words
- case reportsCase ReportsShort papers that describe clinical cases of geriatric interest.Length not stated
- commentariesCommentariesCommentaries are invited short papers referring to an article published in High Blood Pressure & Cardiovascular Prevention.Length not stated
- correspondenceReview ArticlesOverview papers on selected topics. Review articles are in general invited by the editors but suggestions by interested individuals may also be c…Length not stated
- editorialReview ArticlesOverview papers on selected topics. Review articles are in general invited by the editors but suggestions by interested individuals may also be c…Length not stated
- letterReview ArticlesOverview papers on selected topics. Review articles are in general invited by the editors but suggestions by interested individuals may also be c…main text ≤ 1,000 words
- letters to the editorLetters to the EditorBrief letters (maximum of 1.000 words including max 5 references; no tables or figures) may be published if they include the notation “for …Length not stated
- meta-analysisReview ArticlesOverview papers on selected topics. Review articles are in general invited by the editors but suggestions by interested individuals may also be c…Length not stated
- original articlesOriginal articlesAccounts of research or clinical practice that should be based on original rather than confirmatory data.Length not stated
- original research paperReview ArticlesOverview papers on selected topics. Review articles are in general invited by the editors but suggestions by interested individuals may also be c…main text ≤ 5,000 words
- reviewReview ArticlesOverview papers on selected topics. Review articles are in general invited by the editors but suggestions by interested individuals may also be c…Length not stated
- review articleReview ArticlesOverview papers on selected topics. Review articles are in general invited by the editors but suggestions by interested individuals may also be c…main text ≤ 7,500 words
- review articlesReview ArticlesOverview papers on selected topics. Review articles are in general invited by the editors but suggestions by interested individuals may also be c…Length not stated
- short communicationReview ArticlesOverview papers on selected topics. Review articles are in general invited by the editors but suggestions by interested individuals may also be c…main text ≤ 2,000 words
- short communicationsShort communicationsShort communication may represent either a final report on definitive studies which do not require a larger space for complete documentation…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Trial registration / reporting guidelines
- AI use Generative AI Images
LLMs do not satisfy authorship criteria; use of LLMs must be documented in the Methods section. Model summary
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
Journal is a member of COPE and follows COPE guidelines on misconduct. Model summary
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright Copyright and license term – CC BY-NC
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution-NonCommercial 4.0 International License Find more about the license agreement Back to top
Source ↗Publisher website ·- Open access Open access publishing
Open Choice articles are published under CC BY-NC 4.0 with copyright retained by authors. Model summary
To find out more about publishing your work Open Access in High Blood Pressure & Cardiovascular Prevention, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Frequency
- 6 issues per year
- ISSN
- 1120-9879
- Electronic ISSN
- 1179-1985
- Latest issue on the website
- Volume 33, Issue 5 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about High Blood Pressure & Cardiovascular Prevention
What CAS zone is High Blood Pressure & Cardiovascular Prevention in?
In the 2025 upgraded edition of the CAS Journal Ranking, High Blood Pressure & Cardiovascular Prevention is in Zone 3 of Medicine, and in Zone 4 of the minor category Peripheral Vascular Disease. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of High Blood Pressure & Cardiovascular Prevention?
The journal's website gives an impact factor of 2.9 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 5.5, h-index 47.
How long does peer review take at High Blood Pressure & Cardiovascular Prevention?
Based on the dates recorded on 88 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 74 days (interquartile range 45–107 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of High Blood Pressure & Cardiovascular Prevention?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Reference style: Numbered, in order of citation; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of High Blood Pressure & Cardiovascular Prevention based?
Of the 104 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Italy (55), United States (10) and Switzerland (6). Counted from the institutions listed on the board page; for reference only.
Which databases index High Blood Pressure & Cardiovascular Prevention?
According to LetPub and DOAJ records, High Blood Pressure & Cardiovascular Prevention is indexed in ESCI and Scopus. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is High Blood Pressure & Cardiovascular Prevention open access, and what is the APC?
High Blood Pressure & Cardiovascular Prevention is a hybrid journal. For open-access publication: APC about USD 2,890.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .